<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003569</url>
  </required_header>
  <id_info>
    <org_study_id>DS 97-39</org_study_id>
    <secondary_id>RPCI-DS-9739</secondary_id>
    <secondary_id>BIONUM-BNP7787IV101</secondary_id>
    <secondary_id>NCI-G98-1478</secondary_id>
    <nct_id>NCT00003569</nct_id>
  </id_info>
  <brief_title>Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel</brief_title>
  <official_title>Phase I Trial of Escalating Doses of BNP7787 in Patients With Solid Tumors Undergoing Treatment With Cisplatin and Taxol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Chemoprotective drugs such as dimesna may protect normal cells from&#xD;
      the side effects of chemotherapy.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of dimesna in treating&#xD;
      patients with solid tumors who are receiving cisplatin and paclitaxel.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) of dimesna administered prior to cisplatin&#xD;
           and paclitaxel in patients with solid tumors.&#xD;
&#xD;
        -  Determine the dose related qualitative and quantitative side effects of dimesna&#xD;
           administered on this schedule in these patients.&#xD;
&#xD;
        -  Determine the minimum safe volume of intravenous hydration after the determination of&#xD;
           the MTD of dimesna in these patients.&#xD;
&#xD;
        -  Investigate the possible protective side effects of dimesna in reducing or preventing&#xD;
           the development of cisplatin induced nephrotoxicity and observe possible protective&#xD;
           effects against cisplatin or paclitaxel related neurotoxicity and myelosuppression in&#xD;
           these patients.&#xD;
&#xD;
        -  Investigate the pharmacokinetic behavior of dimesna in the plasma and urine on this&#xD;
           schedule of administration in this patient population.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, two-stage, multicenter study.&#xD;
&#xD;
      During stage I, patients receive a single dose of dimesna IV over 15 minutes 7 days prior to&#xD;
      chemotherapy. Patients then receive paclitaxel IV over 3 hours followed by dimesna IV over&#xD;
      15-30 minutes followed immediately by cisplatin IV over 1 hour on day 1 every 3 weeks.&#xD;
      Patients continue courses of paclitaxel, dimesna, and cisplatin every 3 weeks in the absence&#xD;
      of disease progression or unacceptable toxicity for up to 6 courses.&#xD;
&#xD;
      In stage I, cohorts of 3-6 patients each receive escalating doses of dimesna until the&#xD;
      maximum tolerated dose (MTD) is reached. The MTD is defined as the highest dose at which no&#xD;
      more than 1 of 6 patients experiences dose limiting toxicity (DLT). The MTD of dimesna is&#xD;
      then used in stage II of the study, in which the volume of pre and post cisplatin intravenous&#xD;
      saline hydration is reduced in cohorts of 3-6 patients each. The MTD intensity of cisplatin&#xD;
      is defined as the least saline hydration volume at which no more than 1 of 6 patients&#xD;
      experience DLT.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 35 patients will be accrued into this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1998</start_date>
  <primary_completion_date type="Actual">June 2003</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <enrollment type="Actual">2</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Neurotoxicity</condition>
  <condition>Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dimesna</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-small cell lung cancer, ovarian&#xD;
             carcinoma, squamous cell carcinoma of the head and neck, tumor types for which no&#xD;
             standard treatment exists, or tumor types that have failed standard therapy&#xD;
&#xD;
          -  Paclitaxel and cisplatin combination therapy must be an appropriate option in treating&#xD;
             disease&#xD;
&#xD;
          -  No potentially curable type of cancer (e.g., newly diagnosed testicular cancer)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 6 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC greater than 4,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,500/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  SGOT and SGPT normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No evidence of congestive heart failure&#xD;
&#xD;
          -  No uncontrolled moderate to severe hypertension&#xD;
&#xD;
          -  Includes patients with persistent elevated systolic blood pressures of greater than&#xD;
             170 mm Hg and diastolic blood pressures of greater than 100 mm Hg for more than 1&#xD;
             month while under medical treatment&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No perceived or actual clinical risk of cisplatin induced toxicity that exceeds the&#xD;
             clinical benefit of using cisplatin therapy&#xD;
&#xD;
          -  No known history of severe hypersensitivity to polyoxyl 35 castor oil vehicle&#xD;
&#xD;
          -  No severe medical problems unrelated to malignancy that would interfere with&#xD;
             compliance in this study&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Effective contraception required of all fertile patients&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent colony stimulating factors except for febrile neutropenia&#xD;
&#xD;
          -  No concurrent aminoglycoside therapy except for febrile neutropenia or other life&#xD;
             threatening infections&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 6 weeks since prior nitrosoureas or mitomycin&#xD;
&#xD;
          -  At least 3 weeks since other prior chemotherapy&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy to measurable disease&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 2 weeks since prior major surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick J. Creaven, MBBS, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 30, 2013</last_update_submitted>
  <last_update_submitted_qc>January 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2013</last_update_posted>
  <keyword>stage III non-small cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>neurotoxicity</keyword>
  <keyword>recurrent salivary gland cancer</keyword>
  <keyword>stage IV salivary gland cancer</keyword>
  <keyword>salivary gland squamous cell carcinoma</keyword>
  <keyword>stage III salivary gland cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

